(AOF) – The listed French company Hybrigenics today announces its repositioning under the name Aton, marking the completion of the transformation begun two years ago. The company’s new visual identity and rebranding aims to position it as a leading player in the pharmaceutical and biotechnology industry. The doubling of Aton’s workforce planned over the next two years “will strengthen its capabilities and accelerate research and development efforts”.
A French company created in 1998, Aton is made up of four entities: “Bcell Design”, a specialist in premium quality antibodies for the in vitro diagnostic (IVD), research and development of therapeutic products sectors; “Inoviem Scientific” which supports biotech companies by accelerating and securing the entire development process of their drugs; “Pims Technology” which “develops an analysis instrument designed to personalize treatments, ensuring that they are adapted to the needs of patients”, and “Stemcis” which “manufactures surgical kits intended for lipofilling”.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.